Hint mode is switched on Switch off

Relmada Therapeutics, ordinary share
RLMD, US75955J4022

Add a stock to WL
Choose all Reset all
Relmada Therapeutics, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

Profile
Relmada Therapeutics, Inc. is a clinical stage, public specialty pharmaceutical company who develops a variety of established drug products. The Company also researches and procures chemical entities with a focus on the treatment of pain.
  • Issuer
  • Full borrower / issuer name
    Relmada Therapeutics, Inc
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    RLMD
  • Placement
    05.12.2019
  • Lock up period
    180
  • Number of papers
    3,333,334
  • Volume of raised funds
    100 mln USD
  • Placement share
    24.3%
  • Final placement price
    30 USD
  • Price change since placement date
    -80.23%
  • By capitalization
    411.5 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    RLMD
  • Placement
    10.12.2021
  • Lock up period
    180
  • Number of papers
    8,823,530
  • Volume of raised funds
    150 mln USD
  • Placement share
    33.42%
  • Final placement price
    17 USD
  • Price change since placement date
    -65.12%
  • By capitalization
    448.84 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    RLMD
  • Placement
    05.11.2025
  • Lock up period
    180
  • Number of papers
    40,142,000
  • Volume of raised funds
    88.31 mln USD
  • Placement share
    54.74%
  • Final placement price
    2.2 USD
  • Price change since placement date
    169.55%
  • By capitalization
    161.33 mln USD
Other placements of the issuer Hide

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide

Related Stock indices

Indicators

News

05/05/2026 Adeia (NASDAQ: ADEA) Stock Gains Momentum with Strong Q1 Earnings and Analyst Upgrade
09/03/2026 Relmada Therapeutics: Entry Into A Material Definitive Agreement, Unregistered Sales Of Equity Securities, Regulation Fd Disclosure, Other Events, Financial Statements And Exhibits
12/12/2025 Relmada Therapeutics: Financial Statements And Exhibits
04/11/2025 Relmada Therapeutics: Entry Into A Material Definitive Agreement, Regulation Fd Disclosure, Financial Statements And Exhibits
15/09/2025 Relmada Therapeutics: Other Events, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.